Is Retatrutide FDA approved?

No. Drugs@FDA holds no approved application for it, checked on 2026-08-28. That check is worth stating precisely because the same query returns six applications for semaglutide, so the absence is a real answer rather than a failed search — about approval only, since Drugs@FDA does not list applications under review. Until an application is approved there is no legal route to buy it in the United States outside a clinical trial, at any price.

What does Retatrutide cost?

Nothing, because it cannot be bought. There is no list price, no cash price and no savings program, and any figure circulating is either a forecast or an invention. When it is approved and sold, it will get a card on this site with the price, its source and the date it was read, the same as everything else here.

Retatrutide is sold online as a research peptide. Is that the same drug?

It shares a name and nothing that can be checked. The molecule in Lilly's trials comes with a manufacturing chain a regulator has inspected and a dose someone is accountable for; a research-peptide vial comes with a disclaimer saying it is not for human use, which is the seller's own statement that it is not a medicine. There is no approved label to compare a copy against, because there is no approved product — so nobody, including the buyer, can say what a given vial contains.

Retatrutide: when can you actually buy it?

You cannot: Retatrutide holds no approved application in the United States. It is a triple agonist, hitting the GIP, GLP-1 and glucagon receptors in one weekly injection, developed by Eli Lilly and Company. Every other page on this site carries a price; this one carries the public record there is instead — the phase 3 trial program.

When will Retatrutide be available, and what will it cost?

No approval date has been published by anyone, and no price exists because nothing is for sale. What is public is the trial program. Retatrutide has 9 phase 3 trials in obesity or overweight registered on ClinicalTrials.gov, enrolling 8,757 people between them, the largest of them 2,335. 4 have completed and 5 are still running, with the last reaching primary completion in October 2028. A sponsor can file on part of a program rather than wait for the whole of it, so these dates neither bound nor predict an approval; a filing is the event to watch. Drugs@FDA was checked on 2026-08-28 and holds no approved application for this molecule, against six for semaglutide — a finding about approval, not about filing, because Drugs@FDA does not list applications still under review.

The trial program

Sponsor	Eli Lilly and Company
Approved in the US	no — no approved application in Drugs@FDA
Phase 3 trials in obesity or overweight	9
Completed	4 of 9
Still running	5
Participants enrolled across them	8,757
Largest single trial	2,335 participants
Last primary completion	October 2028

Counted from ClinicalTrials.gov on 2026-08-28, restricted to phase 3 studies whose registered condition is obesity, overweight or weight. Approval status checked against Drugs@FDA the same day.

What is worth knowing now

Retatrutide is the most searched of the three and the one most often sold illegally, under the label of a research peptide. That trade is worth being plain about: a vial bought that way is not the drug in the trials. It has no approved label, no verified content, no pharmacy accountable for what is in it, and no FDA registration behind whoever made it — the differences that this site spends most of its pages measuring, absent all at once. No legitimate version exists yet: nothing is approved, and five of nine phase 3 obesity studies are still running, the last reaching primary completion in October 2028.

Retatrutide, answered

Is Retatrutide FDA approved?: No. Drugs@FDA holds no approved application for it, checked on 2026-08-28. That check is worth stating precisely because the same query returns six applications for semaglutide, so the absence is a real answer rather than a failed search — about approval only, since Drugs@FDA does not list applications under review. Until an application is approved there is no legal route to buy it in the United States outside a clinical trial, at any price.
When will Retatrutide be available?: Nobody has published a date, and no filing is reported on this page. 5 of its 9 phase 3 trials in obesity or overweight are still running, and the last reaches primary completion in October 2028. That is not a floor either: a company can file on part of a program rather than wait for all of it, so what brings an approval into view is a filing.
What does Retatrutide cost?: Nothing, because it cannot be bought. There is no list price, no cash price and no savings program, and any figure circulating is either a forecast or an invention. When it is approved and sold, it will get a card on this site with the price, its source and the date it was read, the same as everything else here.
Retatrutide is sold online as a research peptide. Is that the same drug?: It shares a name and nothing that can be checked. The molecule in Lilly's trials comes with a manufacturing chain a regulator has inspected and a dose someone is accountable for; a research-peptide vial comes with a disclaimer saying it is not for human use, which is the seller's own statement that it is not a medicine. There is no approved label to compare a copy against, because there is no approved product — so nobody, including the buyer, can say what a given vial contains.

What you can buy today

Everything approved for this job, each with the maintenance price, its source and the date it was read.

All three, side by side →Every verified price, ranked →Which drugs are actually GLP-1s →Why it gets called GLP-3 →Survodutide →CagriSema →

Last updated 2026-08-28 — trial registry and Drugs@FDA checked. Read and dated by Alex Seot.